Istituto Oncologico Veneto

Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit

Neoplasms Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Melanoma Medicine & Life Sciences
Survival Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2018 2018

I. O. V. - NUOVI MODELLI ORGANIZZATIVI: PDTA E INDICATORI

Ricerca, U.

1/1/1812/30/18

Project: Other project

I. O. V. - IMMUNOLOGIA DEI TUMORI

Ricerca, U.

1/1/1812/30/18

Project: Other project

I. O. V. - ONCOLOGIA SPERIMENTALE

Ricerca, U.

1/1/1812/30/18

Project: Other project

Research Output 1974 2018

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Conte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., Russo, A. & 12 othersPronzato, P., Giovanardi, F., Moretti, G., Lombardo, L., Schirone, A., Beano, A., Amaducci, L., Bajardi, E. A., Vicini, R., Balduzzi, S., D'Amico, R. & Guarneri, V., Sep 13 2018, In : Annals of oncology : official journal of the European Society for Medical Oncology.

Research output: Contribution to journalArticle

Combination Drug Therapy
Disease-Free Survival
Bayes Theorem
Breast Neoplasms
Drug Therapy
1 Citations
fotemustine
Carmustine
Melphalan
Hematopoietic Stem Cell Transplantation
Cytarabine

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Maugeri Centre for Telehealth and Telecare (MCTT), 2018, In : The Lancet Oncology. 19, 4, p. 474-485 12 p.

Research output: Contribution to journalArticle